ArticleEJNMMI research2018
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.Cancer medicine · 2026Trial
- Review
- Now you see me: lights on Merkel Cell Carcinoma.European journal of hybrid imaging · 2023Article
- Combined treatment with radiotherapy, chemotherapy and avelumab results in regression of metastatic Merkel cell carcinoma and improvement of associated Lambert-Eaton myasthenic syndrome: A case report.Oncology letters · 2022Article
- PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.Cancers · 2022Review
- Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?International journal of molecular sciences · 2021Review
- High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma.The British journal of dermatology · 2021Article
- Positron Emission Tomography in Merkel Cell Carcinoma.Cancers · 2020Review
- [Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Review
- Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions.Journal of cancer research and clinical oncology · 2019Review
- Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know.Radiographics : a review publication of the Radiological Society of North America, IncReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMerkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently,
resultsFifteen patients (12 males, 3 females; median age 73 years; range 41-81 years) with histologically proven MCC (4 with unknown primary lesion) who underwent both
conclusionsOur preliminary data suggest that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.